Protara Therapeutics, Inc. (TARA)

NASDAQ: TARA · IEX Real-Time Price · USD
3.20
+0.24 (8.11%)
Oct 3, 2022 4:00 PM EDT - Market closed
8.11%
Market Cap 36.06M
Revenue (ttm) n/a
Net Income (ttm) -40.30M
Shares Out 11.27M
EPS (ttm) -3.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,496
Open 2.99
Previous Close 2.96
Day's Range 2.93 - 3.27
52-Week Range 2.72 - 7.97
Beta 1.50
Analysts Buy
Price Target 34.43 (+975.9%)
Earnings Date Nov 2, 2022

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed ... [Read more...]

Industry Biotechnology
CEO Jesse Shefferman
Employees 31
Stock Exchange NASDAQ
Ticker Symbol TARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TARA stock is "Buy." The 12-month stock price forecast is 34.43, which is an increase of 975.94% from the latest price.

Price Target
$34.43
(975.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

3 weeks ago - GlobeNewsWire

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: GRNAKINDNILE
1 month ago - Benzinga

Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

1 month ago - GlobeNewsWire

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 A...

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today an...

4 months ago - GlobeNewsWire

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

4 months ago - GlobeNewsWire

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable...

5 months ago - Zacks Investment Research

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

6 months ago - GlobeNewsWire

Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 687.9% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable...

6 months ago - Zacks Investment Research

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way -

6 months ago - GlobeNewsWire

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

7 months ago - GlobeNewsWire

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today a...

8 months ago - GlobeNewsWire

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

8 months ago - GlobeNewsWire

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete –

10 months ago - GlobeNewsWire

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today a...

11 months ago - GlobeNewsWire

11 Things to Know About Protara Therapeutics as TARA Stock Soars on Big FDA News

Protara Therapeutics (TARA) stock is heading higher on Tuesday following some major news from the FDA concerning clinical trials. The post 11 Things to Know About Protara Therapeutics as TARA Stock Soar...

11 months ago - InvestorPlace

Why Protara Therapeutics Stock Is Rising Today

Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invas...

11 months ago - Benzinga

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment o...

- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -

11 months ago - GlobeNewsWire

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End -

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -

1 year ago - GlobeNewsWire

Why Novavax, Inovio, and Protara Are Moving Today

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...

Other symbols: INONVAX
1 year ago - Benzinga

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations Company to conduct additional clinical study to support subm...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...

1 year ago - GlobeNewsWire

Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview

- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End -

1 year ago - GlobeNewsWire